None
Quote | Marker Therapeutics Inc. (NASDAQ:MRKR)
Last: | $4.335 |
---|---|
Change Percent: | -6.02% |
Open: | $4.58 |
Close: | $4.335 |
High: | $4.65 |
Low: | $4.1101 |
Volume: | 16,017 |
Last Trade Date Time: | 03/27/2024 03:00:00 am |
News | Marker Therapeutics Inc. (NASDAQ:MRKR)
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
2024-03-26 01:13:20 ET More on Marker Therapeutics Financial information for Marker Therapeutics Read the full article on Seeking Alpha For further details see: Marker Therapeutics GAAP EPS of -$1.59, revenue of $3.31M
Message Board Posts | Marker Therapeutics Inc. (NASDAQ:MRKR)
Subject | By | Source | When |
---|---|---|---|
https://finance.yahoo.com/news/marker-therapeutics-reports-mt-401-110000404.html | abracky | investorshub | 06/26/2023 4:10:50 PM |
https://www.globenewswire.com/en/news-release/2023/06/26/2694294/0/en/Marker-The | jobynimble | investorshub | 06/26/2023 1:19:31 PM |
My pleasure | jobynimble | investorshub | 06/26/2023 1:13:54 PM |
So my obvious question would be: with all | microcapbiotech | investorshub | 06/26/2023 1:10:23 PM |
non-clinical data on its lead multi-tumor-associated antigen (multiTAA)-specific | microcapbiotech | investorshub | 06/26/2023 1:04:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH...
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on develo...